Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection

Key Inclusion Criteria: * Participants who failed treatment in Study GS-US-334-0119 who meet relevant inclusion/exclusion criteria are eligible for retreatment in this study * Chronic genotype 1 HCV infection * HCV treatment-naive * HCV RNA \> 10,000 IU/mL at screening * Absence of cirrhosis * Screening laboratory values within defined thresholds * Use of two effective contraception methods if female of childbearing potential or sexually active male Key Exclusion Criteria: * Pregnant or nursing female or male with pregnant female partner * Infection with hepatitis B virus (HBV) * Current or prior history of clinical hepatic decompensation * Chronic use of systemic immunosuppressive agents * History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol * For HIV-1/HCV co-infected individuals: * Opportunistic infection within 6 months prior to screening * Active, serious infection (other than HIV-1 or HCV) requiring parental antibiotics, antivirals or antifungals within 30 days prior to baseline * Treatment with an antiretroviral (ARV) regimen other than one of those listed in the study protocol Note: Other protocol defined Inclusion/Exclusion criteria may apply.